Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe RA according to 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) joint criteria~* Treatment with tocilizumab SC monotherapy for up to 8 weeks prior to enrollment, under the prescriptive authority of a physician who has made the decision to commence tocilizumab in accordance with the local label~* Methotrexate intolerance, or inadequate response to prior DMARDs and TNF inhibitors where continued methotrexate treatment was deemed inappropriate~Exclusion Criteria:~* Treatment with tocilizumab more than 8 weeks prior to enrollment~* Failure to meet local tocilizumab label indication criteria~* Treatment with any investigational agent within 4 weeks of beginning tocilizumab SC monotherapy~* Last methotrexate dose within 1 week of beginning tocilizumab SC monotherapy~* History of any other autoimmune or joint inflammatory disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab for RA in Routine Clinical Practice (Type: None): Participants from routine clinical practice in Hungary who are receiving treatment for RA with tocilizumab SC according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling and who have no contraindication to tocilizumab therapy as per the local label are eligible for observation.

Based on this trial design, predict the completion outcome and termination type (if applicable).